{"prompt": "['Novartis', 'Confidential', 'Page 46', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', \"The Investigator must also contact the IRT to register the patient's discontinuation from study\", 'treatment.', '9.1.2', 'Withdrawal of informed consent', 'Subjects may voluntarily withdraw consent to participate in the study for any reason at any time.', 'Withdrawal of consent occurs only when a subject:', 'Does not want to participate in the study anymore, and', 'Does not allow further collection of personal data', 'In this situation, the Investigator should make a reasonable effort (e.g. telephone, e-mail or letter)', \"to understand the primary reason for the subject's decision to withdraw his/her consent and\", 'record this information.', 'Study treatment must be discontinued and no further assessments conducted, and the data that', 'would have been collected at subsequent visits will be considered missing.', 'Further attempts to contact the subject are not allowed unless safety findings require', 'communicating or follow-up.', 'All efforts should be made to complete the assessments prior to study withdrawal. A final', \"evaluation at the time of the subject's study withdrawal should be made as detailed in the\", 'assessment table.', 'Novartis will continue to keep and use collected study information (including any data resulting', \"from the analysis of a subject's samples until their time of withdrawal) according to applicable\", 'law.', 'For US: All biological samples not yet analyzed at the time of withdrawal may still be used for', 'further testing/analysis in accordance with the terms of this protocol and of the informed consent', 'form.', 'For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no', 'longer be used, unless permitted by applicable law. They will be stored according to applicable', 'legal requirements.', '9.1.3', 'Lost to follow-up', 'For subjects whose status is unclear because they fail to appear for study visits without stating', 'an intention to discontinue or withdraw, the Investigator must show \"due diligence\" by', 'documenting in the source documents steps taken to contact the subject, e.g. dates of telephone', 'calls, registered letters, etc. A subject should not be considered as lost to follow-up until due', 'diligence has been completed or until the end of the study.', '9.1.4', 'Early study termination by the sponsor', 'The study can be terminated by Novartis at any time for any reason. This may include reasons', 'related to the benefit/ 1 risk assessment of participating in the study, practical reasons (including', 'slow enrollment), or for regulatory or medical reasons. In taking the decision to terminate,', 'Novartis will always consider the patient welfare and safety. Should early termination be', 'necessary, patients must be seen as soon as possible (provide instruction for contacting the']['Novartis', 'Confidential', 'Page 47', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'patient, when the patient should stop taking drug, when the patient should come for a final visit)', 'and treated as a prematurely withdrawn patient. The Investigator may be informed of additional', 'procedures to be followed in order to ensure that adequate consideration is given to the', \"protection of the patient's interests. The Investigator or sponsor depending on the local\", 'regulation will be responsible for informing IRBs/IECs of the early termination of the trial.', '9.2', 'Study completion and post-study treatment', 'A patient will be considered to have completed the study when the patient has completed the', 'last visit planned in the protocol. Study completion for a patient will occur after he/she has', 'completed 16-weeks of treatment (through the follow-up visit) or they have prematurely', 'withdrawn. Completion of the study will be when all randomized patients have completed 16', 'weeks of treatment and the post-treatment follow-up visit.', 'Patients who have been screened when enrolment target has been met will be allowed to proceed', 'onto study participation.', 'For all patients a safety follow-up visit should be conducted (e.g. by telephone) 14 days after', 'last visit (Week 16). The information to be collected at this follow up visit includes adverse', 'events, concomitant medications and SAEs.', 'When the patient has completed all scheduled study assessments or prematurely withdrawn', 'from the study, the Investigator must contact the IRT to record the patient completion', '/discontinuation and complete applicable eCRF', '10', 'Safety monitoring and reporting', '10.1', 'Definition of adverse events and reporting requirements', '10.1.1', 'Adverse events', 'An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and', 'unintended sign (including abnormal laboratory findings), symptom or disease) in a subject or', 'clinical investigation subject after providing written informed consent for participation in the', 'study. Therefore, an AE may or may not be temporally or causally associated with the use of a', 'medicinal (investigational) product.', 'The Investigator has the responsibility for managing the safety of individual subject and', 'identifying adverse events.', 'Novartis qualified medical personnel will be readily available to advise on trial related medical', 'questions or problems.', 'The occurrence of adverse events must be sought by non-directive questioning of the subject at', 'each visit during the study. Adverse events also may be detected when they are volunteered by', 'the subject during or between visits or through physical examination findings, laboratory test', 'findings, or other assessments.']\n\n###\n\n", "completion": "END"}